Recommendations for the Use of Testosterone in Male Transgender*

Detalhes bibliográficos
Autor(a) principal: Costa,Laura Bregieiro Fernandes
Data de Publicação: 2018
Outros Autores: Rosa-e-Silva,Ana Carolina Japur de Sá, Medeiros,Sebastião Freitas de, Nacul,Andrea Prestes, Carvalho,Bruno Ramalho de, Benetti-Pinto,Cristina Laguna, Yela,Daniela Angerame, Maciel,Gustavo Arantes Rosa, Soares Júnior,José Maria, Maranhão,Técia Maria de Oliveira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de ginecologia e obstetrícia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032018000500275
Resumo: Abstract Gender incongruence is defined as a condition in which an individual self-identifies and desires to have physical characteristics and social roles that connote the opposite biological sex. Gender dysphoria is when an individual displays the anxiety and/or depression disorders that result from the incongruity between the gender identity and the biological sex. The gender affirmation process must be performed by a multidisciplinary team. The main goal of the hormone treatment is to start the development of male physical characteristics by means of testosterone administration that may be offered to transgender men who are 18 years old or over. The use of testosterone is usually well tolerated and improves the quality of life. However, there is still lack of evidence regarding the effects and risks of the long-term use of this hormone. Many different pharmacological formulations have been used in the transsexualization process. The most commonly used formulation is the intramuscular testosterone esters in a short-term release injection, followed by testosterone cypionate or testosterone enanthate. In the majority of testosterone therapy protocols, the male physical characteristics can be seen in almost all users after 6 months of therapy, and themaximum virilization effects are usually achieved after 3 to 5 years of regular use of the hormone. To minimize risks, plasmatic testosterone levels should be kept within male physiological ranges (300 to 1,000 ng/dl) during hormonal treatment. It is recommended that transgender men under androgen therapy be monitored every 3 months during the 1st year of treatment and then, every 6 to 12 months.
id FEBRASGO-1_4dffb509d455c51971ba026854fe9fe0
oai_identifier_str oai:scielo:S0100-72032018000500275
network_acronym_str FEBRASGO-1
network_name_str Revista brasileira de ginecologia e obstetrícia (Online)
repository_id_str
spelling Recommendations for the Use of Testosterone in Male Transgender*transgender mengender incongruencegender dysphoriaAbstract Gender incongruence is defined as a condition in which an individual self-identifies and desires to have physical characteristics and social roles that connote the opposite biological sex. Gender dysphoria is when an individual displays the anxiety and/or depression disorders that result from the incongruity between the gender identity and the biological sex. The gender affirmation process must be performed by a multidisciplinary team. The main goal of the hormone treatment is to start the development of male physical characteristics by means of testosterone administration that may be offered to transgender men who are 18 years old or over. The use of testosterone is usually well tolerated and improves the quality of life. However, there is still lack of evidence regarding the effects and risks of the long-term use of this hormone. Many different pharmacological formulations have been used in the transsexualization process. The most commonly used formulation is the intramuscular testosterone esters in a short-term release injection, followed by testosterone cypionate or testosterone enanthate. In the majority of testosterone therapy protocols, the male physical characteristics can be seen in almost all users after 6 months of therapy, and themaximum virilization effects are usually achieved after 3 to 5 years of regular use of the hormone. To minimize risks, plasmatic testosterone levels should be kept within male physiological ranges (300 to 1,000 ng/dl) during hormonal treatment. It is recommended that transgender men under androgen therapy be monitored every 3 months during the 1st year of treatment and then, every 6 to 12 months.Federação Brasileira das Sociedades de Ginecologia e Obstetrícia2018-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032018000500275Revista Brasileira de Ginecologia e Obstetrícia v.40 n.5 2018reponame:Revista brasileira de ginecologia e obstetrícia (Online)instname:Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)instacron:FEBRASGO10.1055/s-0038-1657788info:eu-repo/semantics/openAccessCosta,Laura Bregieiro FernandesRosa-e-Silva,Ana Carolina Japur de SáMedeiros,Sebastião Freitas deNacul,Andrea PrestesCarvalho,Bruno Ramalho deBenetti-Pinto,Cristina LagunaYela,Daniela AngerameMaciel,Gustavo Arantes RosaSoares Júnior,José MariaMaranhão,Técia Maria de Oliveiraeng2018-07-20T00:00:00Zoai:scielo:S0100-72032018000500275Revistahttp://www.scielo.br/rbgohttps://old.scielo.br/oai/scielo-oai.phppublicações@febrasgo.org.br||rbgo@fmrp.usp.br1806-93390100-7203opendoar:2018-07-20T00:00Revista brasileira de ginecologia e obstetrícia (Online) - Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)false
dc.title.none.fl_str_mv Recommendations for the Use of Testosterone in Male Transgender*
title Recommendations for the Use of Testosterone in Male Transgender*
spellingShingle Recommendations for the Use of Testosterone in Male Transgender*
Costa,Laura Bregieiro Fernandes
transgender men
gender incongruence
gender dysphoria
title_short Recommendations for the Use of Testosterone in Male Transgender*
title_full Recommendations for the Use of Testosterone in Male Transgender*
title_fullStr Recommendations for the Use of Testosterone in Male Transgender*
title_full_unstemmed Recommendations for the Use of Testosterone in Male Transgender*
title_sort Recommendations for the Use of Testosterone in Male Transgender*
author Costa,Laura Bregieiro Fernandes
author_facet Costa,Laura Bregieiro Fernandes
Rosa-e-Silva,Ana Carolina Japur de Sá
Medeiros,Sebastião Freitas de
Nacul,Andrea Prestes
Carvalho,Bruno Ramalho de
Benetti-Pinto,Cristina Laguna
Yela,Daniela Angerame
Maciel,Gustavo Arantes Rosa
Soares Júnior,José Maria
Maranhão,Técia Maria de Oliveira
author_role author
author2 Rosa-e-Silva,Ana Carolina Japur de Sá
Medeiros,Sebastião Freitas de
Nacul,Andrea Prestes
Carvalho,Bruno Ramalho de
Benetti-Pinto,Cristina Laguna
Yela,Daniela Angerame
Maciel,Gustavo Arantes Rosa
Soares Júnior,José Maria
Maranhão,Técia Maria de Oliveira
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Costa,Laura Bregieiro Fernandes
Rosa-e-Silva,Ana Carolina Japur de Sá
Medeiros,Sebastião Freitas de
Nacul,Andrea Prestes
Carvalho,Bruno Ramalho de
Benetti-Pinto,Cristina Laguna
Yela,Daniela Angerame
Maciel,Gustavo Arantes Rosa
Soares Júnior,José Maria
Maranhão,Técia Maria de Oliveira
dc.subject.por.fl_str_mv transgender men
gender incongruence
gender dysphoria
topic transgender men
gender incongruence
gender dysphoria
description Abstract Gender incongruence is defined as a condition in which an individual self-identifies and desires to have physical characteristics and social roles that connote the opposite biological sex. Gender dysphoria is when an individual displays the anxiety and/or depression disorders that result from the incongruity between the gender identity and the biological sex. The gender affirmation process must be performed by a multidisciplinary team. The main goal of the hormone treatment is to start the development of male physical characteristics by means of testosterone administration that may be offered to transgender men who are 18 years old or over. The use of testosterone is usually well tolerated and improves the quality of life. However, there is still lack of evidence regarding the effects and risks of the long-term use of this hormone. Many different pharmacological formulations have been used in the transsexualization process. The most commonly used formulation is the intramuscular testosterone esters in a short-term release injection, followed by testosterone cypionate or testosterone enanthate. In the majority of testosterone therapy protocols, the male physical characteristics can be seen in almost all users after 6 months of therapy, and themaximum virilization effects are usually achieved after 3 to 5 years of regular use of the hormone. To minimize risks, plasmatic testosterone levels should be kept within male physiological ranges (300 to 1,000 ng/dl) during hormonal treatment. It is recommended that transgender men under androgen therapy be monitored every 3 months during the 1st year of treatment and then, every 6 to 12 months.
publishDate 2018
dc.date.none.fl_str_mv 2018-05-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032018000500275
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032018000500275
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1055/s-0038-1657788
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
publisher.none.fl_str_mv Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
dc.source.none.fl_str_mv Revista Brasileira de Ginecologia e Obstetrícia v.40 n.5 2018
reponame:Revista brasileira de ginecologia e obstetrícia (Online)
instname:Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
instacron:FEBRASGO
instname_str Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
instacron_str FEBRASGO
institution FEBRASGO
reponame_str Revista brasileira de ginecologia e obstetrícia (Online)
collection Revista brasileira de ginecologia e obstetrícia (Online)
repository.name.fl_str_mv Revista brasileira de ginecologia e obstetrícia (Online) - Federação Brasileira das Sociedades de Ginecologia e Obstetrícia (FEBRASGO)
repository.mail.fl_str_mv publicações@febrasgo.org.br||rbgo@fmrp.usp.br
_version_ 1754115944083357696